Market revenue in 2023 | USD 8,000.8 million |
Market revenue in 2030 | USD 17,586.1 million |
Growth rate | 11.9% (CAGR from 2023 to 2030) |
Largest segment | Bioreactors/fermenters |
Fastest growing segment | Cell Culture Products |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioreactors/Fermenters, Cell Culture Products, Filters, Bioreactors Accessories, Bags & Containers |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Corning Inc, Sartorius AG, Eppendorf, Danaher Corp, Boehringer Ingelheim, Getinge AB Class B, Lonza Group Ltd, Avantor Inc, Repligen Corp, Entegris Inc, PBS Biotech, Meissner, Kuhner Shaker |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to upstream bioprocessing market will help companies and investors design strategic landscapes.
Bioreactors/fermenters was the largest segment with a revenue share of 31.18% in 2023. Horizon Databook has segmented the U.S. upstream bioprocessing market based on bioreactors/fermenters, cell culture products, filters, bioreactors accessories, bags & containers covering the revenue growth of each sub-segment from 2018 to 2030.
Key companies such as GE Healthcare, Danaher Life Sciences, and Avantor, Inc. that offer a wide product portfolio to support upstream workflows in bioproduction have contributed to market growth in the U.S. These key companies are engaged in several business initiatives to advance in bioprocessing and strengthen their market position.
These bioreactors are expected to simplify single-use upstream bioprocessing procedures. Furthermore, in September 2023, Waters launched new solutions to simplify the cell culture media and biological drug product analysis. Over traditional methods, the solutions optimize the development of upstream bioprocess approximately by six weeks.
Furthermore, the ongoing national conferences that provide insights into various innovations in upstream bioprocessing are driving product uptake in the country. Moreover, in August 2023, Cambridge Innovation Institute (CII) held its 16th Bioprocessing Summit. It emphasized existing methods of improving bioprocessing, the bioprocessing future, and the potential transformation in the coming years.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. upstream bioprocessing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. upstream bioprocessing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account